Population Pharmacokinetic–Pharmacodynamic Analysis of Neutropenia in Cancer Patients Receiving PM00104 (Zalypsis®)

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

(2012) T A Yap et al.   BRITISH JOURNAL OF CANCER

Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors

(2012) C. Massard et al.   INVESTIGATIONAL NEW DRUGS

Population pharmacokinetics of PM00104 (Zalypsis®) in cancer patients

(2011) Carlos Pérez-Ruixo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model

(2010) Angelica Linnea Quartino et al.   INVESTIGATIONAL NEW DRUGS

Molecular pharmacology and antitumor activity of Zalypsis ® in several human cancer cell lines

(2009) Juan F.M. Leal et al.   BIOCHEMICAL PHARMACOLOGY

Zalypsis (PM00104) is a potent inducer of  -H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition

(2009) J. Guirouilh-Barbat et al.   MOLECULAR CANCER THERAPEUTICS

Semi-Mechanistic Model for Neutropenia after High Dose of Chemotherapy in Breast Cancer Patients

(2009) Amelia Ramon-Lopez et al.   PHARMACEUTICAL RESEARCH

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks

(2008) E. M. Ocio et al.   BLOOD

Using Pharmacokinetic and Pharmacodynamic Modeling and Simulation to Evaluate Importance of Schedule in Topotecan Therapy for Pediatric Neuroblastoma

(2008) J. C. Panetta et al.   CLINICAL CANCER RESEARCH